Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Abarceo Pharma AB logo — Developing the first disease modifying and durable treatment...

Abarceo Pharma AB

Developing the first disease modifying and durable treatment for type 2 and type 1 diabetes.

Founded 2017 Sweden Sweden 9 employees Venture round Total: $21.50M Biotechnology, Health and Wellness +1

General Information

Company Name Abarceo Pharma AB
Founded Year 2017
Location Sweden Sweden
Employees 9
Industries Biotechnology, Health and Wellness, Pharmaceutical
Funding Stage Venture round
Social

BounceWatch is an independent company data service, not affiliated with Abarceo Pharma AB. To contact Abarceo Pharma AB, visit abarceo.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Abarceo Pharma AB compare?

A PDF of Abarceo Pharma AB and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Abarceo Pharma AB soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Abarceo Pharma AB

Abarceo Pharma AB is a preclinical stage company dedicated to developing the first disease modifying and durable treatment for type 2 and type 1 diabetes. The company's expertise in the molecular and genetic causes of beta cell dysfunction in type 2 diabetes has led to the identification of a novel diabetes target - VDAC-1. A small molecule blocker developed by Abarceo Pharma AB can block VDAC-1, thereby restoring beta cells to a functional state in a durable and disease modifying manner, enabling patients to naturally produce sufficient insulin. Founded in 2017, Abarceo Pharma AB operates in the Biotechnology, Health and Wellness, and Pharmaceutical industries. The company's latest fundraising round saw a kr21.50M Venture Round investment on 01 March 2021 from Almi Invest, aimed at supporting their preclinical development efforts.

Business keywords: Diabetes treatment, Biotech startup, Molecular biology, Drug development, Genetic research, Beta cell dysfunction, Preclinical stage, Type 2 diabetes therapy, Lund University Diabetes Center, Small molecule blocker, VDAC-1 target, Alzheimer's research, Mitochondrial medicine, Scientific founders, Disease modification

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round kr21.50M 1
Almi Invest
Almi Invest
01 Mar 2021
Venture Round Undisclosed 1
LU Innovation
08 Sep 2020

Abarceo Pharma AB Alternatives & Competitors

View All Alternatives
Abarceo Pharma AB vs
Lexeo Therapeutics
Lexeo Therapeutics United States

Advancing science with curative potential for both cardiovascular and APOE4 associated Alzheimer's d...

Post-IPO Equity
97 employees
Biotechnology, Health and Wellness
Abarceo Pharma AB vs
Ashvattha Therapeutics, Inc.
Ashvattha Therapeutics, Inc. United States

Harnessing the power of hydroxyl dendrimers to create a new class of disease cell-targeted precision...

Series B
24 employees
Biotechnology, Health Care
Abarceo Pharma AB vs
Tract Bio
Tract Bio United States

Discovering and developing novel therapies to transform the treatment of cancer and inflammatory dis...

2 employees
Health and Wellness, Life Sciences
View all alternatives

FAQ About Abarceo Pharma AB

Developing the first disease modifying and durable treatment for type 2 and type 1 diabetes.
Abarceo Pharma AB was founded in 2017.
Abarceo Pharma AB is headquartered in Sweden.
Abarceo Pharma AB operates in Biotechnology, Health and Wellness and Pharmaceutical. Its work centres on Diabetes treatment, Biotech startup, Molecular biology and Drug development.
Abarceo Pharma AB has approximately 9 employees.
Abarceo Pharma AB has completed 2 funding rounds, raising a total of $21.50M. The latest funding stage is Venture round.
Top alternatives and competitors to Abarceo Pharma AB include Lexeo Therapeutics, Ashvattha Therapeutics, Inc., Tract Bio, Genprex, Inc., SAB BIO. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Abarceo Pharma AB and Lexeo Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Abarceo Pharma AB, https://bouncewatch.com/company/abarceo-pharma-ab, updated 20 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes